Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial, which evaluated daratumumab maintenance therapy in patients with newly diagnosed, transplant-eligible myeloma.
Jacob Laubach on Long-Term Results With Daratumumab Plus RVd
By Jacob Laubach, MD, MPP - Last Updated: November 14, 2022Advertisement
Related Posts
The approval is based on the DREAMM-7 and DREAMM-8 trials, in which belantamab mafodotin showed favorable survival benefit.
Experts call for rethinking smoldering myeloma as a distinct disease, with new data supporting early risk-based intervention.
Experts discuss the link between dietary patterns and blood cancer risk and the shortcomings of epidemiological studies.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.